|
The University of Nebraska Medical Center
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Stage Ii, Iii And IV Peripheral T-Cell Non-Hodgkin’s Lymphoma
INVESTIGATOR: Andy Evens, DO, MSc
SPONSOR: The University of Nebraska Medical Center
Combined Study at clinicaltrials.gov
ECOG E2408
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
INVESTIGATOR: Andy Evens, DO, MSc
SPONSOR: Eastern Cooperative Oncology Group (ECOG)
ECOG E2408 at clinicaltrials.gov
SWOG 0816
A phase 2 trial of response-adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging
INVESTIGATOR: Andy Evens, DO, MSc
SPONSOR: NCI/Southwest Oncology Group
SWOG 0816 at clinicaltrials.gov
CALGB 50604
A Phase II Trial of Response-adapted Chemotherapy Based on Positron Emission Tomography for Non-bulky Stage I and II Hodgkin Lymphoma
INVESTIGATOR: Andy Evens, DO, Msc
SPONSOR: CALGB (Cancer And Leukemia Group B)
CALGB 50604 at clinicaltrials.gov
Northwestern University
Protocol NU11H01: A phase II trial of sequential SGN35 therapy with Adriamycin, vinblastine, and dacarbazine (S-AVD) for older patients with untreated Hodgkin lymphoma
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Northwestern University
Northwestern University at clinicaltrials.gov
Spectrum Pharmaceuticals, Inc
SPI-MGD-11-201: A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin (ibritumomab tiuxetan) versus Zevalin and motexafin gadolinium in Patients with Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin’s Lymphoma
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals at clinicaltrials.gov
|